Age-Dependent Memory Benefits From Pharmacologically Enhanced Naps?
The purpose of this study is to investigate whether 1. pharmacologically enhanced naps will show increases in specific sleep stages 2. whether these sleep stages will produces specific increases on memory tests 3. whether older adults will benefit more than young adults from increased SWS or Stage 2 on subsequent declarative and motor memory tests...
Brief Summary
The purpose of this study is to investigate whether
1. pharmacologically enhanced naps will show increases in specific sleep stages
2. whether these sleep stages will produces specific increases on memory tests
3. whether older adults will benefit more than young adults from increased SWS or Stage 2 on subsequent declarative and motor memory tests.
- Study Type: Interventional
- Study Design: N/A
- Study Primary Completion Date: June 2009
Intervention(s) in this Clinical Trial
- Drug: Sodium Oxybate
- 2.5g Sodium Oxybate administered during nap
- Drug: Zolpidem
- 5mg Zolpidem administered during nap
- Drug: placebo
- Placebo administered during nap
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: Sodium Oxybate
- 2.5g Sodium Oxybate administered during nap
- Experimental: Zolpidem
- 5mg Zolpidem administered during nap
- Placebo Comparator: Placebo
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- English-speaking individuals, half men and half women, and between the ages of 60 and 75 years will be recruited. No ethnic group will be specifically excluded from study.
- All participants will be recruited from general San Diego Community. An education requirement of at least 12 years completed will be imposed, as education may affect performance on the cognitive task.
Exclusion Criteria:
- Not having a regular sleep-wake schedule (defined as not meeting criteria listed above and/or a Horne-Ostberg Morningness-Eveningness Questionnaire score not between 31-69)
- Having a sleep disorder (reported or detected on the questionnaires)
- Any personal or immediate family (i.e., first degree relative) history of diagnosed significant psychopathology
- Personal history of head injury with loss of consciousness greater than 15 minutes or seizures
- History of substance dependence
- Current use of any psychotropic medications
- Any cardiac, respiratory or other medical condition which may affect cerebral metabolism
- Given the nature of the stimulus and its presentation, anyone with non-correctable vision and audition impairments will also be excluded.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 60 Years
Maximum Age for this Clinical Trial: 75 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: University of California, San Diego Other
Overall Clinical Trial Officials and Contacts
Overall Contact: Jen Kanady, BA 858-642-3192 jkanady@vapop.ucsd.edu
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00773032
Study ID Number: 071529_OA
ClinicalTrials.gov Identifier: NCT00773032
Health Authority: United States: Federal Government
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00773032
